Autres langues IMPACT Therapeutics, Inc

Actions

Marché Fermé - Hong Kong S.E. 10:08:14 13/08/2026			Varia. 5j.	Varia. 1 janv.
12,11 ^HKD	-7,84%		-6,12%	-

31/07	IMPACT Therapeutics, Inc et Pharmanovia concluent un accord de licence exclusif pour le senaparib en Europe, au Moyen-Orient, en Afrique du Nord, en Australie et en Nouvelle-Zélande	CI
27/07	IMPACT Therapeutics, Inc. annonce la nomination de l'IMP3201 comme candidat préclinique, un ADC à double charge ciblant CEACAM5 premier de sa classe	CI

31/07	IMPACT Therapeutics, Inc and Pharmanovia Enter Exclusive License Agreement For Senaparib In Europe, Middle East And North Africa, Australia And New Zealand
31/07	IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
27/07	IMPACT Therapeutics, Inc Announces IMP3201 As A Preclinical Candidate, A First-In-Class CEACAM5-Targeted Dual-Payload ADC
27/07	Impact Therapeutics Nominates Preclinical Candidate for GI Cancers
20/07	Impact Therapeutics Announces Clinical Data for Senaparib, IMP4297, and IMP1707 Accepted for Poster Presentation at 2026 ESMO Congress
08/06	Impact Therapeutics Nets HK$120 Million From Full Exercise of IPO Overallotment Option
01/06	Impact Therapeutics, Inc Presents Phase 1/2 Clinical Data for Imp1734 At 2026 Asco Annual Meeting
13/05	Hong Kong Stocks Eke Out Gains; Metis TechBio, Impact Therapeutics Shine on Debut
13/05	Impact Therapeutics Jumps 77% in Hong Kong Trading Debut
13/05	Impact Therapeutics Nets HK$759.5 Million From Hong Kong IPO Ahead of Debut
12/05	IMPACT Therapeutics, Inc has completed an IPO in the amount of HKD 843.7377 million.
12/05	Impact Therapeutics says final offer price under global offering of HK$20.10 per H share
05/05	IMPACT Therapeutics, Inc has filed an IPO in the amount of HKD 913.20964 million.
05/05	IMPACT Therapeutics, Inc Reports Earnings Results for the Full Year Ended December 31, 2025